[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Viruses. 2019 Nov 15;11(11). pii: E1066. doi: 10.3390/v11111066.
Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
Kiso M1, Yamayoshi S1, Furusawa Y1, Imai M1, Kawaoka Y1,2,3.
Author information: 1 Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan. 2 Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA. 3 Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Viral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. Here, we examined the efficacy of baloxavir marboxil in mice infected with a highly pathogenic human H7N9 virus, A/Guangdong/17SF003/2016. Treatment of infected mice with a single 1.5 mg/kg dose of baloxavir marboxil protected mice from the highly pathogenic human H7N9 virus infection as effectively as oseltamivir treatment at 50 mg/kg twice a day for five days. Daily treatment for five days at 15 or 50 mg/kg of baloxavir marboxil showed superior therapeutic efficacy, largely preventing virus replication in respiratory organs. These results indicate that baloxavir marboxil is a valuable candidate treatment for human patients suffering from highly pathogenic H7N9 virus infection.
KEYWORDS: H7N9; baloxavir marboxil; highly pathogenic; influenza
PMID: 31731678 DOI: 10.3390/v11111066
Keywords: Antivirals; Avian Influenza; H7N9; Baloxavir Marboxil; Animal models.